Phase 4 N=90 Combination Therapy for Atopic Dermatitis
Atopic Dermatitis
Primary: Change From Baseline in the m-EASI (Eczema Area Severity Index) Score. — 5.04; 4.77 units of a 0-12 scale — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 Kaletra: Therapy With Double Protease Inhibitors
Human Immunodeficiency Virus
Primary: Percentage of Participants With Human Immunodeficiency Virus -1 Ribonucleic Acid (HIV-1 RNA) <50 Copies/mL — 8.6; 26.2; 40.0; 56.3 percentage of participants
Phase 3 N=1,008 Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx
Relapsing Remitting Multiple Sclerosis
Primary: ARR - PDEs — 0.12; 0.16; 0.11 relapses per year
Phase 3 N=2,492 Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension
Hypertension
Primary: Change From Baseline to Week 12 in Seated Diastolic Blood Pressure (SeDBP). — -17.8; -16.5; -14.8; -21.5 mm Hg — p=<0.0001
Phase 2 N=4 Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL
Cutaneous T-cell Lymphoma · Mycosis Fungoides · Sezary Syndrome
Primary: Number of Participants With a 50% Improvement in Baseline Skin Score — 0 participants
Phase 2 N=20 Combination Drug-Therapy for Patients With Untreated Obstructive Sleep Apnea
OSA · Obstructive Sleep Apnea
Primary: Apnea Hypopnea Index (AHI) — 17.1; 32.7; 26; 23.6 events/hour of sleep
Phase 2 N=229 Combination Therapy for Chronic Hepatitis C Infection
Hepatitis C, Chronic
Primary: The Proportion of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs — 100; 95; 95; 91.2 percentage of subjects
Phase 1 N=131 A Study to Test the Combination of Two Different Kinds of Medications for the Treatment of Diabetes
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 6-Month Endpoint — -0.08; 0.06; -0.15; 0.04 percent glycosylated hemoglobin (HbA1c) — p=0.623
N/A N=774 'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor
HIV Infections
Primary: Number of Treatment-naïve Participants With Human Immunodeficiency Virus Ribonucleic Acid (HIV-RNA) Levels Less Than (<)50 Copies/Milliliter (c/mL) at 24 Weeks After 2DR…
Phase 4 N=100 Combination Therapy in Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Number of Patients Reaching a 6-Minute Walk Test (6MWT) Distance ≥ 380 Meters — 16; 24 participants
Phase 3 N=792 ODYSSEY (PENTA 20)
HIV Infection
Primary: Difference in Proportion With Failure (Clinical or Virological) — 0; 3; 0; 0 Participants — p== 0.004
Phase 3 N=2,244 Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension
Hypertension
Primary: Difference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 12 — -4.0; 1.4; -1.5; 0.4 mmHg — p=<.0001
Phase 4 N=665 Combining Medications to Enhance Depression Outcomes
Major Depressive Disorder
Primary: Quick Inventory of Depressive Symptoms — 46.6; 41.8; 46.0 percentage of participants
Phase 3 N=247 The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Change From Baseline to Week 26 in Pulmonary Vascular Resistance (PVR) — 0.46; 0.48 ratio — p=0.4239
Phase 4 N=999 A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure
Hypertension
Primary: The Percentage of Patients Who Achieve Seated Systolic Blood Pressure Goal (<140 mm Hg for Non-diabetics and <130 mm Hg for Diabetics) From Baseline to 12 Weeks — 75.8…
Phase 4 N=318 Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM
Diabetes
Primary: HbA1c Level — 6.9; 6.4 percentage of glycated hemoglobin
Phase 4 N=55 Triple Combination Therapy in High Risk Crohn's Disease (CD)
Crohn Disease
Primary: Percentage of Participants Achieving Endoscopic Remission at Week 26 — 34.5 percentage of participants
N/A N=1,096 Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Biguanides
Surveillance
Primary: Number of Participants Reporting One or More Adverse Drug Reactions — 26; 2 participants
Phase 1 N=48 Pharmacokinetics of Fixed Dose Combination (FDC) Tablets of Linagliptin /Metformin
Healthy
Primary: Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval 0 to 72 Hours (AUC0-72) — 248; 251; 266; 264 nmol*h/L
Phase 3 N=305 Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.
Diabetes Mellitus · Dyslipidemias
Primary: The Mean Increase From Baseline in High-Density Lipoprotein Cholesterol. — 3.2; -0.3 mg/dL — p=0.0018
Phase 4 N=20 Combo-PEP: Multipurpose Prevention of Post-Exposure Prophylaxis Regimens
Sexually Transmitted Diseases
Primary: Rectal Doxycycline Concentration — 0.654 µg/g
Phase 2 N=35 Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Primary: Complete Response Rate — 21; 9; 2 Participants
Phase 4 N=221 Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPD
Pulmonary Disease, Chronic Obstructive
Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) (in Liter) After 28 Days of Treatment — 1.422; 1.399 Liter — p=<0.0001
Phase 3 N=520 Initial Combination With Pioglitazone Study (0431-064)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 — -2.38; -1.49 Percent — p=<0.001
Phase 3 N=108 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Childhood Acute Promyelocytic Leukemia With PML-RARA · Myeloid Neoplasm
Primary: Event-free Survival (EFS) — 95.4; 82.9 Percentage of participants
Phase 3 N=192 Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) at Week 12 — 24.62; 25.12; -10.03; -9.18 mmHg
Phase 3 N=262 Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 18 — -1.03; -0.31 Percent — p=<0.001
N/A N=1,374 Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Combination Therapy With Thiazolidinediones"
Type 2 Diabetes Melitus
Primary: Number of Participants Reporting One or More Adverse Drug Reactions — 1; 0; 1; 0 participants
Phase 3 N=200 Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension
Hypertension
Primary: Mean Reduction In Systolic Blood Pressure (SBP) After 18 Weeks of Treatment From Baseline — 150.6; 151.6; -24.7; -25.9 millimeters of mercury (mmHg) — p=<0.001
Phase 3 N=185 Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Two-Sample T-Test — 25.42; 24.43; -10.45; -8.28 Millimeters of Mercury (mmHg)